Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hugh R Barrett

Showing results (71-80 of 143) with videos related to

Pageof 15
Sort By:
Arteriosclerosis, Thrombosis, and Vascular Biology|June 21, 2008
Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndromeDick C Chan, Gerald F Watts, Esther M M Ooi, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 2009
Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese menDick C Chan, P Hugh R Barrett, Esther M M Ooi, et al.
The Journal of Clinical Endocrinology and Metabolism|May 8, 2002
Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesityDick C Chan, Gerald F Watts, P Hugh R Barrett, et al.
Clinical Chemistry|August 29, 2009
Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?Dick C Chan, Gilles Lambert, P Hugh R Barrett, et al.
The American Journal of Clinical Nutrition|January 24, 2003
Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesityDick C Chan, Gerald F Watts, Trevor A Mori, et al.
The Journal of Clinical Endocrinology and Metabolism|January 11, 2007
Postprandial lipoprotein metabolism in familial hypobetalipoproteinemiaAmanda J Hooper, Ken Robertson, P Hugh R Barrett, et al.
Journal of Lipid Research|November 30, 2006
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatinDawn E Telford, Brian G Sutherland, Jane Y Edwards, et al.
Journal of Lipid Research|July 1, 2008
Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptorEmma M Allister, Erin E Mulvihill, P Hugh R Barrett, et al.
Clinical Chemistry|January 15, 2005
Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolismDick C Chan, Gerald F Watts, Theodore W K Ng, et al.
European Heart Journal|March 23, 2018
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kineticsGerald F Watts, Dick C Chan, Ransi Somaratne, et al.
Pageof 15

Showing results (71-80 of 143) with videos related to

Sort By:
Pageof 15
Arteriosclerosis, Thrombosis, and Vascular Biology|June 21, 2008
Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndromeDick C Chan, Gerald F Watts, Esther M M Ooi, et al.
The Journal of Clinical Endocrinology and Metabolism|January 1, 2009
Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese menDick C Chan, P Hugh R Barrett, Esther M M Ooi, et al.
The Journal of Clinical Endocrinology and Metabolism|May 8, 2002
Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesityDick C Chan, Gerald F Watts, P Hugh R Barrett, et al.
Clinical Chemistry|August 29, 2009
Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?Dick C Chan, Gilles Lambert, P Hugh R Barrett, et al.
The American Journal of Clinical Nutrition|January 24, 2003
Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesityDick C Chan, Gerald F Watts, Trevor A Mori, et al.
The Journal of Clinical Endocrinology and Metabolism|January 11, 2007
Postprandial lipoprotein metabolism in familial hypobetalipoproteinemiaAmanda J Hooper, Ken Robertson, P Hugh R Barrett, et al.
Journal of Lipid Research|November 30, 2006
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatinDawn E Telford, Brian G Sutherland, Jane Y Edwards, et al.
Journal of Lipid Research|July 1, 2008
Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptorEmma M Allister, Erin E Mulvihill, P Hugh R Barrett, et al.
Clinical Chemistry|January 15, 2005
Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolismDick C Chan, Gerald F Watts, Theodore W K Ng, et al.
European Heart Journal|March 23, 2018
Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kineticsGerald F Watts, Dick C Chan, Ransi Somaratne, et al.
Pageof 15